Cell delivery systems: Toward the next generation of cell therapies for type 1 diabetes.

Dang, HP; Chen, H; Dargaville, TR; Tuch, BE

Cell delivery systems: Toward the next generation of cell therapies for type 1 diabetes.

Dang, HP Chen, H

Dargaville, TR Tuch, BE

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: J Cell Mol Med, 2022, 26, (18), pp. 4756-4767
Issue Date:: 2022-09

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (2.14 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Dang, HP
dc.contributor.author	Chen, H https://orcid.org/0000-0001-6883-3752
dc.contributor.author	Dargaville, TR
dc.contributor.author	Tuch, BE
dc.date.accessioned	2023-02-23T01:39:33Z
dc.date.available	2022-06-26
dc.date.available	2023-02-23T01:39:33Z
dc.date.issued	2022-09
dc.identifier.citation	J Cell Mol Med, 2022, 26, (18), pp. 4756-4767
dc.identifier.issn	1582-1838
dc.identifier.issn	1582-4934
dc.identifier.uri	http://hdl.handle.net/10453/166359
dc.description.abstract	Immunoprotection and oxygen supply are vital in implementing a cell therapy for type 1 diabetes (T1D). Without these features, the transplanted islet cell clusters will be rejected by the host immune system, and necrosis will occur due to hypoxia. The use of anti-rejection drugs can help protect the transplanted cells from the immune system; yet, they also may have severe side effects. Cell delivery systems (CDS) have been developed for islet transplantation to avoid using immunosuppressants. CDS provide physical barriers to reduce the immune response and chemical coatings to reduce host fibrotic reaction. In some CDS, there is architecture to support vascularization, which enhances oxygen exchange. In this review, we discuss the current clinical and preclinical studies using CDS without immunosuppression as a cell therapy for T1D. We find that though CDS have been demonstrated for their ability to support immunoisolation of the grafted cells, their functionality has not been fully optimized. Current advanced methods in clinical trials demonstrate the systems are partly functional, physically complicated to implement or inefficient. However, modifications are being made to overcome these issues.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	WILEY
dc.relation	Australian Foundation for Diabetes Research
dc.relation.ispartof	J Cell Mol Med
dc.relation.isbasedon	10.1111/jcmm.17499
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0304 Medicinal and Biomolecular Chemistry, 0601 Biochemistry and Cell Biology, 1103 Clinical Sciences
dc.subject.classification	Biochemistry & Molecular Biology
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Humans
dc.subject.mesh	Immunosuppression Therapy
dc.subject.mesh	Islets of Langerhans
dc.subject.mesh	Islets of Langerhans Transplantation
dc.subject.mesh	Oxygen
dc.subject.mesh	Islets of Langerhans
dc.subject.mesh	Humans
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Oxygen
dc.subject.mesh	Islets of Langerhans Transplantation
dc.subject.mesh	Immunosuppression Therapy
dc.title	Cell delivery systems: Toward the next generation of cell therapies for type 1 diabetes.
dc.type	Journal Article
utslib.citation.volume	26
utslib.location.activity	England
utslib.for	0304 Medicinal and Biomolecular Chemistry
utslib.for	0601 Biochemistry and Cell Biology
utslib.for	1103 Clinical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
dc.date.updated	2023-02-23T01:39:21Z
pubs.issue	18
pubs.publication-status	Published
pubs.volume	26
utslib.citation.issue	18

Abstract:

Immunoprotection and oxygen supply are vital in implementing a cell therapy for type 1 diabetes (T1D). Without these features, the transplanted islet cell clusters will be rejected by the host immune system, and necrosis will occur due to hypoxia. The use of anti-rejection drugs can help protect the transplanted cells from the immune system; yet, they also may have severe side effects. Cell delivery systems (CDS) have been developed for islet transplantation to avoid using immunosuppressants. CDS provide physical barriers to reduce the immune response and chemical coatings to reduce host fibrotic reaction. In some CDS, there is architecture to support vascularization, which enhances oxygen exchange. In this review, we discuss the current clinical and preclinical studies using CDS without immunosuppression as a cell therapy for T1D. We find that though CDS have been demonstrated for their ability to support immunoisolation of the grafted cells, their functionality has not been fully optimized. Current advanced methods in clinical trials demonstrate the systems are partly functional, physically complicated to implement or inefficient. However, modifications are being made to overcome these issues.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/166359